Coherus Oncology (NASDAQ:CHRS – Get Free Report) and Zymeworks (NASDAQ:ZYME – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.
Risk & Volatility
Coherus Oncology has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500. Comparatively, Zymeworks has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500.
Earnings & Valuation
This table compares Coherus Oncology and Zymeworks”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Coherus Oncology | $42.17 million | 3.04 | $168.02 million | ($1.03) | -0.81 |
| Zymeworks | $37.13 million | 54.31 | -$81.13 million | ($2.02) | -14.16 |
Coherus Oncology has higher revenue and earnings than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
72.8% of Coherus Oncology shares are owned by institutional investors. Comparatively, 92.9% of Zymeworks shares are owned by institutional investors. 7.2% of Coherus Oncology shares are owned by insiders. Comparatively, 33.5% of Zymeworks shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Analyst Recommendations
This is a summary of current recommendations and price targets for Coherus Oncology and Zymeworks, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Coherus Oncology | 1 | 0 | 3 | 0 | 2.50 |
| Zymeworks | 1 | 1 | 12 | 0 | 2.79 |
Coherus Oncology currently has a consensus price target of $11.00, indicating a potential upside of 1,225.14%. Zymeworks has a consensus price target of $41.67, indicating a potential upside of 45.64%. Given Coherus Oncology’s higher probable upside, equities research analysts plainly believe Coherus Oncology is more favorable than Zymeworks.
Profitability
This table compares Coherus Oncology and Zymeworks’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Coherus Oncology | -259.41% | -222.75% | -52.11% |
| Zymeworks | -405.31% | -72.30% | -37.18% |
Summary
Zymeworks beats Coherus Oncology on 8 of the 14 factors compared between the two stocks.
About Coherus Oncology
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company’s licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
About Zymeworks
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
Receive News & Ratings for Coherus Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
